Philips, Therapeutic Monitoring Systems align on CDS pilot

Luke Gale | | Health Exec | Digital Transformation
partnership - 115.45 Kb
Philips Healthcare and Therapeutic Monitoring Systems are collaborating to integrate clinical decision support (CDS) software, being developed by Ottawa-based Therapeutic Monitoring, into Philips' cardiopulmonary monitors.

Following integration, the CDS-enabled cardiopulmonary monitors will be used in a pilot program at the Ottawa Hospital’s intensive care unit, said the North Andover, Mass.-based Philips. Researchers from the the Ottawa Hospital Research Institute hope the cardiopulmonary monitors are able to reduce patient time spent on mechanical ventilation, prevent ventilator-related complications and improve patient comfort.

Luke Gale

Related Content

2024 in AI weirdness: ‘Insane’ ChatGPT and mutant rat genitals were only the beginning
10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.